

LIBERIA

Support for Pneumococcal Conjugate Vaccine

This Decision Letter sets out the Programme Terms of a Programme

1. Country:	Liberia						
2. Vaccine grant number:	13-LBR-08c-Y, 1315-LBR-12c-X, 16-LBR-12c-X, 1720-LBR-12c-X, 18-LBR-25a-Y, 1820-LBR-12d-X						
3. Date of Decision Letter:	30-Sep-2019						
4. Date of the Partnership Framework Agreement:	19 August 2013						
5. Programme title:	New Vaccine Support (NVS), Pneumococcal , Routine						
6. Vaccine type:	Pneumococcal Conjugate Vaccine						
7. Requested product presentation and formulation of vaccine:	PCV13, 4 doses per vial, LIQUID						
8. Programme Duration:¹	2014-2020						
9. Programme Budget (indicative):²	(subject to the terms of the Partnership Framework Agreement, if applicable)						
	2014-2019	2020	2021	2022	2023	2024	Total²
Programme Budget (US\$)	9,913,878	213,500	-	-	-	-	10,127,378
10. Vaccine introduction grant							
	Approval						
	Year	Grant Number	Amount (US\$)				
	2013	13-LBR-08c-Y	155,000				
	0	-	-				
	Disbursement						
	Disbursement date		Amount (US\$)				
	18 November, 2013		155,000				
11. Product switch grant							
	Approval						
	Year	Grant Number	Amount (US\$)				
	2018	18-LBR-25a-Y	46,007				
	Disbursement						
	Disbursement date		Amount (US\$)				
	17 August, 2018		46,007				
12. Indicative Annual Amounts:³	(subject to the terms of the Partnership Framework Agreement, if applicable)						

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.

Agreement, if applicable)

Type of supplies to be purchased with Gavi funds	2014-2019	2020	2021
Number of vaccine doses		66,800	-
Annual Amounts (US\$)	9,913,878	213,500	-

13. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.

14. Self-procurement: Not applicable

15. Co-financing obligations:

According to the co-financing policy, the Country falls within the group: Initial self-financing

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2020	2021	2022	2023	2024
Number of vaccine doses	5,000	-	-	-	-
Number of AD syringes	-	-	-	-	-
Number of re-constitution syringes	-	-	-	-	-
Number of safety boxes	-	-	-	-	-
Value of vaccine doses (US\$)	14,178	-	-	-	-
Total co-financing payments (US\$) (including freight)	14,500	-	-	-	-

16. Operational support for campaigns:

Not applicable

17. Additional Reporting Requirements:

	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year:	
<ul style="list-style-type: none"> Vaccine stock levels including buffer stock 	31 March 2020
<ul style="list-style-type: none"> Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received 	15 May 2020

<ul style="list-style-type: none"> Country shall report the actual switch date in the first renewal request following the actual implementation. 	
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat
18. Financial clarifications:	Not applicable

Signed by,

On behalf of Gavi



Thabani Maphosa,
Managing Director, Country Programmes
30-Sep-2019